A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Not Recruiting

Trial ID: NCT00959647


This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.

Official Title

An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study

Stanford Investigator(s)

Anthony Oro, MD, PhD
Anthony Oro, MD, PhD

Eugene and Gloria Bauer Professor

Bernice Kwong, MD
Bernice Kwong, MD

Clinical Professor, Dermatology

A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

Anne Lynn S. Chang, MD
Anne Lynn S. Chang, MD

Professor of Dermatology


This study only enrolled participants who took part in previous studies of vismodegib
conducted by Genentech.

Inclusion Criteria:

   - Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study
   or continued to receive vismodegib at the time the Genentech-sponsored parent study

   - Expectation by the investigator that the participant may continue to benefit from
   additional vismodegib treatment.

Exclusion Criteria:

   - Intervening anti-tumor therapy not specified in the parent study (ie,
   non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or
   photodynamic therapy).


drug: bevacizumab


drug: FOLFOX

drug: Vismodegib

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts

Receive email alerts when trials open to patients.